



**meetings
in a box**

ROAD TO



ASCO GU 2026

A cura di Eugenia Cella, Savona

ACC  MED

ACCADEMIA NAZIONALE DI MEDICINA

ROAD TO... ASCO GU 2026

San Francisco 26-28 Feb 2026



PROSTATE CANCER

UROTHELIAL CARCINOMA

RENAL CELL CANCER

PROSTATE CANCER

PEACE-2 (K. Fizazi – LBA307) Phase 3 trial

Very high risk localized prostate cancer ADT+RT+/- Cabazitaxel

PSMAddition (M.J. Morris – Abstract 18) Phase 3 trial

mHSPC PSMA-positive 177u-PSMA-617 +ADT +ARPI

EORTC 1333/PEACE-3 (M.H.A. Hussain – Abstract 15)

Phase 3 trial

mCRPC Enzalutamide +/- Radium-223

UROTHELIAL CARCINOMA

KEYNOTE-B 15 (M.D. Galsky – LBA630) Phase 3 trial

Neoadjuvant Pembolizumab + Enfortumab vedotin muscle-invasive bladder cancer who are eligible for cisplatin.

RC48Go11 (T. Powles et al – LBA631) Phase 2 trial

1L Disitamab vedotin in HER2-expressing previously treated advanced urothelial carcinoma

BIOMARKER-GUIDED PERIOPERATIVE STRATEGIES

Imvigor 11 (T. Powles – Abstract 633)

ctDNA guided adjuvant atezolizumab in MIBC

NIAGARA (M.S. Van der Heijden – Abstract 636)

utDNA and ctDNA in pts received perioperative durvalumab.

RENAL CELL CANCER

LITESPARK-022 (T.K. Choueiri – LBA418) Phase 3 trial

Adjuvant Pembrolizumab +/- Belzutifan for clear cell renal cell carcinoma.

LITESPARK-011 (R.J.Motzer – Abstract 417) Phase 3 trial

>1L Belzutifan + Lenvatinib for advance renal cell carcinoma after anti-PD(L)1 therapy